Popular Articles

Provectus Pharmaceuticals To Offer Compassionate Use Of PV-10 For Non-Visceral Indications In Cancer Patients
Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, has begun a compassionate use program for PV-10 and has made the agent, which is in development as a therapeutic agent for a broad spectrum of cancers, available for select cancer patients.
generic viagra online
First Skin Cancer Patients Treated With Electronic Brachytherapy (eBx) At University Of Wisconsin Riverview Cancer Center
Earlier this month the University of Wisconsin Cancer Center Riverview became the first medical facility in the world to treat patients with a breakthrough treatment of skin cancer. Located within Riverview Hospital, Wisconsin Rapids, the UW Cancer Center Riverview is the first to treat skin cancer patients with the FDA-cleared Axxent(R) Electronic Brachytherapy System from Xoft, Inc. Electronic Brachytherapy, eBx(TM) , delivers a high therapeutic dose to a cancer tumor while sparing nearby normal tissue by using a miniaturized X-ray rather than radioactive isotopes.
News of the day
House Rejects Amendment To HHS Bill To Limit Funding To Planned Parenthood Clinics
The House on Friday voted 264-153 to approve its fiscal year 2010 Labor-HHS-Education spending bill (HB 3293) after voting on five amendments addressing price and policy issues, CQ Today reports. The bill would appropriate $730.5 billion. The Senate Appropriations Committee is scheduled to begin markup of its version of the bill on July 28.The House voted 183-247 to reject an amendment offered by Rep. Mike Pence (R-Ind.) that would have prohibited family planning funding through the Title X program to Planned Parenthood clinics. The House also voted 211-218 to reject an amendment by Rep. Mark Souder (R-Ind.) that would have stripped language to lift the ban on federal funding for needle-exchange programs. Lawmakers did approve an amendment offered by Rep. Darrell Issa (R-Calif.) to strip $5 million in funding for three NIH grants to study the HIV/AIDS risks associated with alcohol and substance use among sex workers in Asia and alcoholics in Russia (Wolfe, CQ Today, 7/24).
Medical Devices

DuoCort: New Chronotherapy For Adrenal Insufficiency

DuoCort publishes data from its Phase I study for the rare and life threatening disease adrenal insufficiency. The release profile of DuoCort"s new form of treatment with once-a-day hydrocortisone dosing closely resembles the physiological secretion pattern. The data is published in the European Journal of Endocrinology, a leading scientific journal for endocrinology. DuoCort"s new drug has been developed to produce a physiological release profile that mimics the body÷´s natural secretion pattern of cortisol to improve outcomes for patients. Results from the phase I study in healthy volunteers, evaluating the safety and pharmacokinetics of the new hydrocortisone tablet, show a physiological diurnal serum cortisol profile after single-dose administration that mimics the natural secretion pattern of cortisol. The new DuoCort therapy showed no absorption failure allowing it to be safely used in patients with adrenal insufficiency. Data from a subsequent phase II/III trial in patients with primary adrenal insufficiency or Addison"s disease, presented at a scientific congress in June confirmed the findings in the phase I study and showed the new therapy to be well tolerated and safe. Endocrinology Professor and Chief Medical Officer of DuoCort, Gudmundur Johannsson says, "We are very pleased with the outcome of the Phase I trial, especially as there was little inter- or intra-individual variability in the pharmacokinetics and the drug release profiles look very like the physiological release profile of cortisol in healthy individuals. This new more physiological chronotherapy has excellent potential to significantly improve cortisol replacement in all types of adrenal insufficiency" Adrenal insufficiency in its untreated state is a highly deadly condition. Current therapy is long outmoded, with no major drug improvements since at least the 1960s. Increasing interest in adrenal insufficiency during the past 10 years has resulted in studies showing premature death, compromised quality of life, increased cardiovascular risk and reduced bone mineral density among patients with adrenal insufficiency. The likely cause is the highly un-physiological glucocorticoid replacement delivered by even the best therapy available today. The large unmet medical need is to improve therapy by mimicking the sizable diurnal variation in serum cortisol that normally occurs. DuoCort seeks to do so by providing a so-called chronotherapy with once-a-day dosing to further enhance the physiological profile. Link to the abstract in European Journal of Endocrinology About adrenal insufficiency Patients suffering from adrenal insufficiency (cortisol deficiency) are unable to produce their own cortisol and need replacement therapy to survive. Adrenal insufficiency is a rare disease that affects patients in their active years and, because it is a chronic condition, they require this life-saving therapy throughout their lives. Treatment of adrenal insufficiency involves replacing, or substituting, the hormones that the adrenal glands are not making. Cortisol is replaced using hydrocortisone, the synthetic form of cortisol, and sometimes with other corticosteroids. There are different types of adrenal insufficiency: primary adrenal insufficiency also called Addison÷´s disease, secondary adrenal insufficiency and CAH- congenital adrenal hyperplasia. About chronotherapy Coordinating biological rhythms (chronobiology) with medical treatment is called chronotherapy. It takes into account the body"s biological rhythms in determining the timing--and sometimes the amount--of medication to optimize a drug"s desired effects and minimize its undesired ones. Chronotherapy for the most part is not about new drug substances but about using medicines in new ways, better attuned to the body"s needs. Designing a drug so its release into the bloodstream has a particular release pattern or using pumps that deliver medicine at specified intervals are some of the innovations that may reap important benefits. DuoCort


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):